The April 15th PR stated that Cytodyne would perform an interim analysis on the Phase 2b/3 trial data from 50 patients. Today NP mentioned that (per the FDA,?) the interim analysis would be at 50% enrollment (~190 patients).

So, yeah, I'm not sure when or how that changed or why.